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Introduction
Criyopyrin associated periodic syndrome (CAPS) has a
heterogenous presentation and in a number patients
mutations can not be found. Here we present our initial
results with CAPS patients.
Case Report
Results
All of our patients had symptoms within the first 3 months
of life. All had fever, urticaria and persistant labaratory
inflammation. All except one patient had failure to thrive.
Except for the one patient with Muckle Wells syndrome
all had neurological features ranging from headache to
convulsions, hydrocephalus, cognitive dysfunction.Two
patients, one without a mutation, had hearing impairment.
Two patients have diarrhea during attacks. All were
started on anti IL1 , one patient who did not respond to
anakinra was started to canakinumab and on the fourth
dose he developed MAS. After MAS was subsided canaki-
numab was re-started and he continues the drug without
further problems. Presently three patients are on anakinra
and three are on canakinumab, all with normal acute
phases and improved quality of life. One patient has
associated Duchenne muscular dystrophy.
Discussion
Conclusions
Anti IL1 treatment is efficacious in CAPS patients.
Somatic mutations may enlighten the mutation negative
patients. Until then classification criteria are needed to
guide pediatricians in diagnosis and treatment.
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